MSK Commercialization Ecosystem
As a global leader in oncology innovation, Memorial Sloan Kettering Cancer Center (MSK) has long been committed to accelerating and scaling the translation of scientific discoveries into inventions that will benefit cancer patients worldwide.
One important way that this happens is through the MSK Commercialization Ecosystem, an evolving and integrated set of funds, infrastructure, and incentives that are holistically designed to accelerate and scale innovation partnering, licensing, investing, and collaboration opportunities.
MSK Clinical Research is also an essential vehicle for promoting and advancing oncology-focused innovation through clinical trials and industry partnerships. Learn more about Clinical Trial innovation at MSK.
Partnering opportunities across a broad array of new technologies and ready-to-use products in MSK’s life sciences, digital health, and related healthcare portfolios
Nurturing and encouraging a culture of entrepreneurship and innovation across MSK to spur startup creation and investment opportunities for our valued industry partners.
Commercialization programs and accelerators which connect industry partners to MSK expertise and resources in order to empower cutting-edge projects with oncology-focused goals.
With an exceptional record of innovation with lasting impact, we look forward to partnering with corporations, investors, and other academic-research organizations on cutting-edge initiatives aimed at improving the diagnosis, early detection, treatment, and care of cancer patients around the world.
Expert professionals and teams throughout our institution are involved in innovative endeavors aimed at improving the diagnosis, treatment, and delivery of care for patients with cancer worldwide.
Uniting MSK’s research and clinical expertise with AWS’s advanced cloud technologies is a bold step towards addressing one of the world’s most pressing health challenges.
Memorial Sloan Kettering Cancer Center (MSK) and Curadev Pharma, Inc., a biotechnology company developing novel immuno-oncology therapeutics, are expanding their collaboration through the MSK Therapeutics Accelerator program to advance the development of CRD3874-SI, Curadev’s first-in-class allosteric stimulator of interferon genes (STING) agonist for solid tumors.
For the first time, MSK has been named one of Fast Company’s Best Workplaces for Innovators, ranking No. 9 out of 100 on its 2025 list of awardees.
